Xu L - Search Results

1

Surgery for small cell lung cancer: A Surveillance, Epidemiology, and End Results (SEER) Survey from 2010 to 2015.

Xu L, Zhang G, Song S, Zheng Z. Xu L, et al. Medicine (Baltimore). 2019 Oct;98(40):e17214. doi: 10.1097/MD.0000000000017214. Medicine (Baltimore). 2019. PMID: 31577711 Free PMC article.

2

Trastuzumab monotherapy for bone marrow metastasis of breast cancer: A case report.

Xu L, Guo F, Song S, Zhang G, Liu Y, Xie X. Xu L, et al. Oncol Lett. 2014 Jun;7(6):1951-1953. doi: 10.3892/ol.2014.1999. Epub 2014 Mar 24. Oncol Lett. 2014. PMID: 24932266 Free PMC article.

3

Case Report: Detection of Double ROS1 Translocations, SDC4-ROS1 and ROS1-GK, in a Lung Adenocarcinoma Patient and Response to Crizotinib.

Xu L, Chen X, Huo H, Liu Y, Yang X, Gu D, Yuan M, Zhang M, Chen R, Wang J, Zheng Z. Xu L, et al. Front Med (Lausanne). 2021 Sep 20;8:649177. doi: 10.3389/fmed.2021.649177. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34616749 Free PMC article.

4

Prognostic factors, treatment, and outcomes in combined small cell lung cancer: a SEER survey from 2004 to 2015.

Xu L, Zhang G, Song S, Zheng Z. Xu L, et al. Transl Cancer Res. 2020 Sep;9(9):5292-5303. doi: 10.21037/tcr-20-968. Transl Cancer Res. 2020. PMID: 35117895 Free PMC article.

5

Single-cell RNA sequencing reveals the mechanism of PI3K/AKT/mTOR signaling pathway activation in lung adenocarcinoma by KRAS mutation.

Xu L, Ding R, Song S, Liu J, Li J, Ju X, Ju B. Xu L, et al. J Gene Med. 2024 Jan;26(1):e3658. doi: 10.1002/jgm.3658. J Gene Med. 2024. PMID: 38282149

6

Investigation of the molecular mechanism of Danggui Buxue tang in treating lung cancer using network pharmacology and molecular docking techniques.

Zhu D, Li S, Xu L, Ren X, Wang S, Chen J, Zhao E, Zheng Z. Zhu D, et al. Among authors: xu l. Nat Prod Res. 2024 Feb 25:1-4. doi: 10.1080/14786419.2024.2305660. Online ahead of print. Nat Prod Res. 2024. PMID: 38403948 Free article.

7

Extensive Stage Small-Cell Lung Cancer with Cystic Brain Metastases: A Report of Two Cases.

Cai F, Wu D, Liu J, Song S, Li J, Zheng Z, Xu L. Cai F, et al. Among authors: xu l. Cancer Manag Res. 2024 Mar 18;16:177-183. doi: 10.2147/CMAR.S449841. eCollection 2024. Cancer Manag Res. 2024. PMID: 38525374 Free PMC article.

8

Icotinib in a lung adenocarcinoma patient with acquired EGFR 19del/C797S mutation-mediated resistance to osimertinib: a case report.

Cai F, Zhao Y, Song S, Zhao D, Zheng Z, Xu L. Cai F, et al. Among authors: xu l. Anticancer Drugs. 2024 Sep 1;35(8):764-768. doi: 10.1097/CAD.0000000000001624. Epub 2024 Jul 16. Anticancer Drugs. 2024. PMID: 38848248

9

The mSHOX2 is capable of assessing the therapeutic effect and predicting the prognosis of stage IV lung cancer.

Peng X, Liu X, Xu L, Li Y, Wang H, Song L, Xiao W. Peng X, et al. Among authors: xu l. J Thorac Dis. 2019 Jun;11(6):2458-2469. doi: 10.21037/jtd.2019.05.81. J Thorac Dis. 2019. PMID: 31372283 Free PMC article.

10

Genomic and Immunological Characterization of Pyroptosis in Lung Adenocarcinoma.

Song Y, Qu Z, Feng H, Xu L, Xiao Y, Zhao Z, Wu D, Sun C, Fan X, Zhou D. Song Y, et al. Among authors: xu l. J Oncol. 2022 Jul 27;2022:6905588. doi: 10.1155/2022/6905588. eCollection 2022. J Oncol. 2022. PMID: 35938142 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

42,019 results

Search Page

Filters